Upsher-Smith to present phase-3 trial data of experimental epilepsy drug

MAPLE GROVE, Minn. – Drug maker Upsher-Smith Labs will present data from a late-stage trial of a drug for treating epilepsy, the company said Monday.

Upsher-Smith's presentation of data from a phase-3 clinical trial of USL255 (topiramate extended-release) will take place at the American Epilepsy Society's 67th annual meeting in Washington, which lasts from Dec. 6-10. Seven presentations will highlight results from the "PREVAIL" trial, while two additional presentations will feature phase-1 trial data on pharmacokinetics of USL255 when sprinkled onto food or swallowed intact.

"This year's AES meeting marks the first time the findings from our phase-3 trial will be presented publicly," Upsher-Smith chief scientific officer William Pullman said. "We look forward to sharing data from the first global phase-3 clinical trial of an extended-release formulation of topiramate with the epilepsy community at this year's annual meeting."